Monte Rosa Therapeutics

22 articles about Monte Rosa Therapeutics

• Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

  3/14/2024

  Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the full year and fourth quarter ended December 31, 2023.

• Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

  3/11/2024

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 -directed MGD.

• Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Jan 31, 2024

  1/31/2024

  Monte Rosa Therapeutics announced that management will participate in the following investor conferences.

• Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

  1/8/2024

  Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, outlined anticipated 2024 milestones ahead of its participation in the 42nd Annual J.P. Morgan Healthcare Conference.

• Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  1/3/2024

  Monte Rosa Therapeutics, Inc. announced that Markus Warmuth, M.D., Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PT.

• Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

  11/21/2023

  Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in New York City on Tuesday, November 28, 2023, at 3:30 p.m. ET.

• Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

  11/9/2023

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the quarter ended September 30, 2023.

• Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

  11/7/2023

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced the company will present preclinical data at the American College of Rheumatology Convergence Annual Meeting held November 10-15 in San Diego, CA.

• Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - October 27, 2023

  10/27/2023

  Monte Rosa Therapeutics today announced that management will participate in the following investor conferences.

• Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

  10/26/2023

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced that it has raised $25 million at-the-market from a life sciences-dedicated investor.

• Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

  10/17/2023

  Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including lung cancers and high-grade neuroendocrine cancer.

• Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

  8/10/2023

  Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the quarter ended June 30, 2023.

• Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors

  7/26/2023

  Monte Rosa Therapeutics, Inc. today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors.

• Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences

  5/30/2023

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced the company is scheduled to present at the following investor and industry events in June.

• Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

  5/23/2023

  Monte Rosa Therapeutics, Inc. today announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1.

• Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

  5/11/2023

  Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, reported business highlights and financial results for the quarter ended March 31, 2023.

• Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

  4/17/2023

  Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today presented preclinical data characterizing MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader designed for the treatment of MYC-driven solid tumors, including lung cancer.

• Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors

  3/23/2023

  Monte Rosa Therapeutics, Inc. today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors.

• Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/16/2023

  Monte Rosa Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided corporate updates.

• Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

  2/3/2023

  Monte Rosa Therapeutics, Inc. today announced the company is scheduled to participate in fireside chats and industry panels, as well as present at the following upcoming investor events.